FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis

BACKGROUND: Doublets plus anti‐epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI‐bevacizumab is superior to doublets plus bevacizumab independently from primar...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Pietrantonio, Filippo, Fucà, Giovanni, Rossini, Daniele, Schmoll, Hans‐Joachim, Bendell, Johanna C., Morano, Federica, Antoniotti, Carlotta, Corallo, Salvatore, Borelli, Beatrice, Raimondi, Alessandra, Marmorino, Federica, Niger, Monica, Boccaccino, Alessandra, Masi, Gianluca, Lonardi, Sara, Boni, Luca, de Braud, Filippo, Di Bartolomeo, Maria, Falcone, Alfredo, Cremolini, Chiara
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2021
Предметы:
Gastrointestinal Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018298/
https://ncbi.nlm.nih.gov/pubmed/33336844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13642
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы